Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.

Author: Lindner, Samuel M. MD; Fordyce, Christopher B. MD, MHS, MSc; Hellkamp, Anne S. MS; Lokhnygina, Yuliya PhD; Piccini, Jonathan P. MD, MHS; Breithardt, Gunter MD; Mahaffey, Kenneth W. MD; Singer, Daniel E. MD; Hacke, Werner MD, PhD; Halperin, Jonathan L. MD; Hankey, Graeme J. MD; Berkowitz, Scott D. MD; Nessel, Christopher C. MD; Becker, Richard C. MD; Fox, Keith A.A. MB, ChB; Patel, Manesh R. MD; On behalf of the ROCKET AF Steering Committee and Investigators

Page: 1001-1003

http://ift.tt/2n8GgKs